An Open, Single-Centre, Randomized, 6-way Crossover, Dose-Response Comparative Study of Esomeprazole 20, 40 and 80 mg and Pantoprazole 20, 40 and 80 mg regarding 24-hour Intragastric pH following 5 Days Repeated Oral Dose Administration in Patients with Symptoms of Gastroesophageal Reflux Disease
Study identifier:D9612C00026
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open, Single-Centre, Randomized, 6-way Crossover, Dose-Response Comparative Study of Esomeprazole 20, 40 and 80 mg and Pantoprazole 20, 40 and 80 mg regarding 24-hour Intragastric pH following 5 Days Repeated Oral Dose Administration in Patients with Symptoms of Gastroesophageal Reflux Disease
Medical condition
gastrointestinal diseases
Phase
Phase 1
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Feb 2006
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
